Pipeline Moves: Alnylam's Amvuttra approval prospects up after Phase III win

Alnylam's Amvuttra shows promise in familial amyloid cardiomyopathy, Shionogi's S-309309 progresses in obesity, and Junshi Biosciences faces setbacks in ovarian cancer trials. These developments impact drug approval and advancement probabilities.